CURCUMIN or turmeric supplementation was associated with a modest but significant reduction in systolic blood pressure in adults with prediabetes or Type 2 diabetes (T2D), according to a new meta-analysis of randomised trials.
Curcumin and Blood Pressure Risk in Diabetes
Hypertension is a common and clinically important comorbidity in people with prediabetes and T2D, substantially increasing the risk of cardiovascular events. Alongside standard antihypertensive therapy, interest has grown in adjunctive nutritional approaches that may address underlying inflammation and oxidative stress. Curcumin, the bioactive compound in turmeric, has demonstrated anti-inflammatory and antioxidant effects in experimental and clinical settings. However, evidence for its impact on blood pressure in people with impaired glucose metabolism has remained inconsistent. A recent meta-analysis was designed to clarify whether curcumin or turmeric supplementation meaningfully improves systolic or diastolic blood pressure in this high-risk population.
Curcumin Trial Design and Analysis
Researchers conducted a systematic review and meta-analysis of randomised controlled trials evaluating curcumin or turmeric supplementation in adults with prediabetes or T2D. 15 trials, comprising 16 treatment arms and a total of 855 participants, met the inclusion criteria. Studies were identified through searches of PubMed, Scopus and Web of Science up to August 2025. A random-effects model was used to account for between-study variability. Outcomes of interest included changes in systolic blood pressure (SBP) and diastolic blood pressure (DBP), with additional subgroup analyses based on baseline hypertension status, body weight, diabetes status, formulation, and dose.
Curcumin Efficacy and Safety Signals
Pooled analysis showed that curcumin or turmeric supplementation significantly reduced SBP by 2.69 mmHg compared with control, with low-to-moderate heterogeneity. The effect was more pronounced in participants with baseline hypertension, where SBP fell by 3.41 mmHg. Significant reductions in SBP were also observed in people with prediabetes or T2D, those who were overweight, and in trials using nano-curcumin, turmeric, or curcumin combined with piperine at doses exceeding 1 g/day. Overall effects on DBP were not statistically significant, although a reduction in DBP was seen in the subgroup of participants with T2D. No major safety concerns were reported across the included trials.
This meta-analysis suggests curcumin supplementation may offer a small but clinically relevant reduction in systolic blood pressure in adults with prediabetes and diabetes, particularly those with established hypertension. Further high-quality trials are needed to confirm efficacy, determine optimal formulations, and define its role alongside conventional blood pressure management.
Reference
Bahari H et al. Antihypertensive Effects of Curcumin/Turmeric Supplementation in Prediabetes and Diabetes: A Systematic Review and Meta-Analysis of Randomised Controlled Trials. Endocrinol Diabetes Metab. 2025;9(1):e70145.
